Study of Nicotinamide Adenine Dinucleotide and Nicotinamide Mononucleotide to Treat Adults with Primary Immune Thrombocytopenia Who Did Not Respond to Standard Treatments

What this Trial Is About

Immune thrombocytopenia ITP is an autoimmune disease that causes a low platelet count leading to bleeding in the skin and mucous membranes. This trial studies the safety and effectiveness of nicotinamide adenine dinucleotide NAD and nicotinamide mononucleotide NMN for treating ITP in patients who have not responded well or have relapsed after first-line and at least one second-line therapy such as Anti-CD20 antibody or TPO receptor agonists. The study addresses the need for better treatments for adults with recurrent or difficult-to-treat ITP, a condition that severely impacts quality of life. Participants receive intravenous NAD 100 mg daily for 1 week and oral NMN 450 mg twice daily for 2 weeks in an open, single-arm design. The study has two stages the first 2 weeks focus on treatment safety and efficacy, followed by a 6-week observation period to monitor ongoing safety and effects after stopping the treatment. During the trial, participants will have regular blood tests to measure platelet counts and bleeding scores, along with tracking any side effects for up to 8 weeks. Researchers will evaluate how well the treatment increases platelet levels and reduces bleeding symptoms. The study also monitors adverse events and treatment tolerability. Overall participation lasts about 8 weeks, including treatment and follow-up assessments.

A Clinical Study of NAD in the Treatment of Immune Thrombocytopenia